{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T03:18:10Z","timestamp":1788923890404,"version":"build-2803163510"},"reference-count":79,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune-mediated inflammatory arthritides (IMIA), including rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and juvenile idiopathic arthritis, are chronic immune-driven disorders in which long-term malignancy safety has become a key determinant of therapeutic decision-making. Patients with IMIA are not oncologically neutral at baseline; persistent inflammatory burden, smoking exposure, age, and cumulative immunosuppressive treatment all modify cancer susceptibility. Against this background, biologic and targeted synthetic disease-modifying antirheumatic drugs may both reduce inflammation-associated oncogenic pressure and attenuate antitumor immune surveillance. In this narrative review, we synthesize current evidence on tumor safety across major biologic classes and Janus kinase inhibitors, with emphasis on data emerging through early 2026. Overall, most biologic therapies appear broadly reassuring with respect to overall malignancy, although non-melanoma skin cancer remains the most reproducible treatment-associated signal, particularly with tumor necrosis factor inhibitors and possibly abatacept. Rituximab retains a favorable profile in patients with prior lymphoproliferative disease, whereas IL-6 and IL-17\/23 pathway inhibitors appear largely neutral or reassuring in currently available datasets. By contrast, JAK inhibitors require greater caution in risk-enriched rheumatoid arthritis populations, especially older patients, smokers, and those with prior malignancy or prolonged treatment exposure. Recent register-based studies have shown that overall cancer incidence with JAK inhibitors is comparable to that with TNF inhibitors, although lung and keratinocyte cancers occur more frequently in certain risk groups; accordingly, updated 2025 EULAR guidance recommends early initiation of targeted therapy after cancer remission and tailoring drug choice to prior cancer type and patient-specific factors. We further examine tumor-type-specific patterns, major modifiers of risk, and practical risk-stratified management strategies. The central clinical message is that malignancy safety in IMIA should be interpreted through an individualized framework that balances inflammatory control against oncologic vulnerability rather than through uniform class-based avoidance.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1827981","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:35:43Z","timestamp":1780551343000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Tumor safety of biologic agents and targeted therapies in immune-mediated inflammatory arthritides"],"prefix":"10.3389","volume":"17","author":[{"given":"Sheng-Guang","family":"Li","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology, Peking University International Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yadan","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Peking University International Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Peking University International Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Peking University International Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Peking University International Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Long","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Peking University International Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruohan","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Peking University International Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfeng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Peking University International Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103410","article-title":"Immune-mediated inflammatory diseases: common and different pathogenic and clinical features","volume":"22","author":"Monteleone","year":"2023","journal-title":"Autoimmun Rev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2103726","article-title":"Rheumatoid arthritis - common origins, divergent mechanisms","volume":"388","author":"Gravallese","year":"2023","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-081860","article-title":"Advances in the management of psoriatic arthritis in adults","volume":"387","author":"Kharouf","year":"2024","journal-title":"BMJ"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.20917","article-title":"Axial spondyloarthritis: a review","volume":"333","author":"Bittar","year":"2025","journal-title":"JAMA"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-024-01079-8","article-title":"Treatment of non-systemic juvenile idiopathic arthritis","volume":"20","author":"Shenoi","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s13075-015-0728-9","article-title":"Incidence of Malignancy in adult patients with rheumatoid arthritis: a meta-analysis","volume":"17","author":"Simon","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"B7","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1136\/annrheumdis-2016-209389","article-title":"Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"76","author":"Mercer","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224049","article-title":"JAK inhibitors and the risk of Malignancy: a meta-analysis across disease indications","volume":"82","author":"Russell","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225982","article-title":"2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer","volume":"84","author":"Sebbag","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/cells11071164","article-title":"Interleukin-6 at the host-tumor interface: STAT3 in biomolecular condensates in cancer cells","volume":"11","author":"Sehgal","year":"2022","journal-title":"Cells"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1479505","article-title":"The role of interleukin-17 in inflammation-related cancers","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/art.40406","article-title":"The tumor-like phenotype of rheumatoid synovium: molecular profiling and prospects for precision medicine","volume":"70","author":"You","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/art.21675","article-title":"Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis","volume":"54","author":"Baecklund","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11122002","article-title":"JAK-STAT signaling: a double-edged sword of immune regulation and cancer progression","volume":"11","author":"Owen","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1901677","article-title":"Abatacept for severe immune checkpoint inhibitor-associated myocarditis","volume":"380","author":"Salem","year":"2019","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.46336","article-title":"Use of biologic or targeted synthetic disease-modifying antirheumatic drugs and cancer risk","volume":"7","author":"Sendaydiego","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70193","article-title":"Comparative safety of biologic and targeted-synthetic DMARDs in patients with rheumatoid arthritis: a multi-database real-world cohort study","volume":"34","author":"Jin","year":"2025","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60071156","article-title":"Anti-TNF alpha and risk of lymphoma in rheumatoid arthritis: a systematic review and meta-analysis","volume":"60","author":"Imam","year":"2024","journal-title":"Med (Kaunas)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f1939","article-title":"Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of Malignant melanoma: nationwide population based prospective cohort study from Sweden","volume":"346","author":"Raaschou","year":"2013","journal-title":"BMJ"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209285","article-title":"Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers","volume":"76","author":"Mercer","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i262","article-title":"Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden","volume":"352","author":"Raaschou","year":"2016","journal-title":"BMJ"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04865-y","article-title":"Risk of non-melanoma skin cancer for rheumatoid arthritis patients receiving TNF antagonist: a systematic review and meta-analysis","volume":"39","author":"Wang","year":"2020","journal-title":"Clin Rheumatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llae503","article-title":"The risk of Malignancy in patients with psoriasis treated with long-term tumour necrosis factor-alpha inhibitors: a systematic review and meta-analysis","volume":"50","author":"Wu","year":"2025","journal-title":"Clin Exp Dermatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2019.03.002","article-title":"Risk of Malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: a multi-database cohort study","volume":"49","author":"Kim","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae140","article-title":"Cancer risk with tocilizumab\/sarilumab, abatacept and rituximab treatment in patients with rheumatoid arthritis: a Danish cohort study","volume":"64","author":"Westermann","year":"2025","journal-title":"Rheumatol (Oxford)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2020.08.007","article-title":"Risk of Malignancy with non-TNFi biologic or tofacitinib therapy in rheumatoid arthritis: a meta-analysis of observational studies","volume":"50","author":"Xie","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20136","article-title":"The risk of Malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up","volume":"185","author":"Lebwohl","year":"2021","journal-title":"Br J Dermatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v102.563","article-title":"Long-term safety of secukinumab over five years in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: update on integrated pooled clinical trial and post-marketing surveillance data","volume":"102","author":"Gottlieb","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1294416","article-title":"Short-term risk and long-term incidence rate of infection and Malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"14","author":"Wu","year":"2023","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2025.2056","article-title":"Ixekizumab and Malignant neoplasms: a pooled analysis of data from 25 randomized clinical trials","volume":"161","author":"Merola","year":"2025","journal-title":"JAMA Dermatol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000002175","article-title":"Risk of Malignancy related to ixekizumab in patients with psoriatic arthritis or axial spondyloarthropathy: systematic review and meta-analysis","volume":"31","author":"Maneiro","year":"2025","journal-title":"J Clin Rheumatol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-024-01238-5","article-title":"Long-term safety of risankizumab in patients with psoriatic disease: a comprehensive analysis from clinical trials","volume":"14","author":"Gordon","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-019-00797-3","article-title":"Ustekinumab safety in psoriasis, psoriatic arthritis, and Crohn's disease: an integrated analysis of phase II\/III clinical development programs","volume":"42","author":"Ghosh","year":"2019","journal-title":"Drug Saf"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key352","article-title":"Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study","volume":"58","author":"Montastruc","year":"2019","journal-title":"Rheumatol (Oxford)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224356","article-title":"Abatacept and non-melanoma skin cancer in patients with rheumatoid arthritis: a comprehensive evaluation of randomised controlled trials and observational studies","volume":"83","author":"Simon","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf114","article-title":"Abatacept and the risk of Malignancy: a meta-analysis across disease indications","volume":"64","author":"Zuckerman","year":"2025","journal-title":"Rheumatol (Oxford)"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-019-00183-6","article-title":"Risk of Malignancies in patients with rheumatoid arthritis treated with rituximab: analyses of global postmarketing safety data and long-term clinical trial data","volume":"7","author":"Emery","year":"2020","journal-title":"Rheumatol Ther"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150051","article-title":"Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years","volume":"42","author":"van Vollenhoven","year":"2015","journal-title":"J Rheumatol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152341","article-title":"Cancer risk with biologic and targeted synthetic DMARDs in patients with rheumatic diseases and previous Malignancies: results from the BIOBADASER register","volume":"64","author":"Molina-Collada","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"B48","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.ard.2025.01.024","article-title":"Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases - a systematic literature review informing the 2024 update of an international expert consensus statement","volume":"84","author":"Konzett","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222543","article-title":"Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial","volume":"82","author":"Curtis","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223715","article-title":"Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance","volume":"82","author":"Kristensen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/art.42250","article-title":"Tofacitinib and risk of Malignancy: Results from the safety of tofacitinib in routine care patients with rheumatoid arthritis (STAR-RA) study","volume":"74","author":"Khosrow-Khavar","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223636","article-title":"Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study","volume":"82","author":"Huss","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.05.014","article-title":"Comparative risk of incident Malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register","volume":"84","author":"Schaefer","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf092","article-title":"Cancer risk of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs among older Americans with rheumatoid arthritis","volume":"64","author":"Ahmed","year":"2025","journal-title":"Rheumatol (Oxford)"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.05.243","article-title":"OP0232\u2005Cancer incidence among rheumatoid arthritis patients treated with JAK-inhibitors compared to bDMARDs: Data from an international collaboration of registers (the \u201cJAK-POT\u201d study)","volume":"84","author":"Aymon","year":"2025","journal-title":"Ann Rheumatic Dis"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001395","article-title":"Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme","volume":"6","author":"Cohen","year":"2020","journal-title":"RMD Open"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221276","article-title":"Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database","volume":"81","author":"Taylor","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002735","article-title":"Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis","volume":"9","author":"Burmester","year":"2023","journal-title":"RMD Open"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03328-y","article-title":"Safety profile of upadacitinib: Descriptive analysis in over 27,000 patient-years across rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, atopic dermatitis, and inflammatory bowel disease","volume":"42","author":"Burmester","year":"2025","journal-title":"Adv Ther"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-21-0125","article-title":"Tumor necrosis factor inhibitors and the risk of cancer among older Americans with rheumatoid arthritis","volume":"30","author":"D'Arcy","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B61","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1186\/s12935-021-02325-9","article-title":"Risk of non-melanoma skin cancer with biological therapy in common inflammatory diseases: a systemic review and meta-analysis","volume":"21","author":"Liu","year":"2021","journal-title":"Cancer Cell Int"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3390\/ph17010014","article-title":"Risk of melanoma and non-melanoma skin cancer in patients with psoriasis and psoriatic arthritis treated with targeted therapies: a systematic review and meta-analysis","volume":"17","author":"Krzysztofik","year":"2023","journal-title":"Pharm (Basel)"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.03.015","article-title":"Rheumatoid arthritis and risk of lung cancer: Meta-analysis and Mendelian randomization study","volume":"51","author":"Wu","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.10.006","article-title":"Rheumatoid arthritis and risk of lung cancer: A nationwide cohort study","volume":"19","author":"Cho","year":"2024","journal-title":"J Thorac Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1002\/art.42961","article-title":"The risk of lung cancer in rheumatoid arthritis and rheumatoid arthritis-associated interstitial lung disease","volume":"76","author":"Brooks","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf103","article-title":"Urological cancer risk in patients with rheumatoid arthritis compared to matched controls: a nationwide cohort study","volume":"64","author":"Lee","year":"2025","journal-title":"Rheumatol (Oxford)"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/art.22277","article-title":"Characteristics of diffuse large B cell lymphomas in rheumatoid arthritis","volume":"54","author":"Baecklund","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002465","article-title":"Risk of lung cancer in rheumatoid arthritis and in relation to autoantibody positivity and smoking","volume":"8","author":"Chatzidionysiou","year":"2022","journal-title":"RMD Open"},{"key":"B69","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s10238-025-01738-4","article-title":"Risk of new or recurrent cancer during treatment with biologics in patients with immune-mediated inflammatory diseases and previous cancer: a meta-analysis","volume":"25","author":"Isufi","year":"2025","journal-title":"Clin Exp Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.05.1401","article-title":"Cutaneous Malignancy after biologic therapy for inflammatory disease: An active comparator, retrospective cohort study","volume":"93","author":"Lauck","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.1300","article-title":"Melanoma risk in patients treated with biologic therapy for common inflammatory diseases: a systematic review and meta-analysis","volume":"156","author":"Esse","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.5534","article-title":"Screening for breast cancer: US Preventive Services Task Force recommendation statement","volume":"331","author":"Force","year":"2024","journal-title":"JAMA"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.4417","article-title":"Screening for colorectal cancer: Updated evidence report and systematic review for the US Preventive Services Task Force","volume":"325","author":"Lin","year":"2021","journal-title":"JAMA"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.6238","article-title":"Screening for colorectal cancer: US Preventive Services Task Force recommendation statement","volume":"325","author":"Force","year":"2021","journal-title":"JAMA"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.1117","article-title":"Screening for lung cancer: US Preventive Services Task Force recommendation statement","volume":"325","author":"Force","year":"2021","journal-title":"JAMA"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-005247","article-title":"Cancer recurrence risk with bDMARD treatment in patients with rheumatoid arthritis and a history of cancer: a nationwide Danish register-based cohort study","volume":"11","author":"Westermann","year":"2025","journal-title":"RMD Open"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2026.02.024","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2025 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"7","author":"Laskou","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002236","article-title":"Waiting for JAK inhibitor safety data","volume":"8","author":"Kragstrup","year":"2022","journal-title":"RMD Open"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1225160","article-title":"The impact of EMA recommendations on the real-life use of Janus kinases inhibitors for rheumatoid arthritis: the Expanded Risk Score in RA as a tool to quantify the risk of cardiovascular events","volume":"14","author":"Favalli","year":"2023","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1827981\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:35:44Z","timestamp":1780551344000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1827981\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":79,"alternative-id":["10.3389\/fimmu.2026.1827981"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1827981","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"article-number":"1827981"}}